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Insulin-like growth factor-binding protein-1 (IG-
FBP-1) binds to insulin-like growth factors (IGFs) and
has been shown to inhibit or stimulate cellular re-
sponses to IGF-I in vitro. This capacity of IGFBP-1 to
inhibit or stimulate IGF-I actions correlates with its
ability to form stable high molecular weight multimers.
Since the ability of some proteins to polymerize is de-
pendent upon transglutamination, we determined if tis-
sue transglutaminase could catalyze this reaction and
the effect of polymerization of IGFBP-1 upon IGF-I ac-
tion. Following incubation with pure tissue transglu-
taminase (Tg), IGFBP-1 formed covalently linked mul-
timers that were stable during SDS-polyacrylamide gel
electrophoresis using reducing conditions. Dephospho-
rylated IGFBP-1 polymerized more rapidly and to a
greater extent compared with native (phosphorylated)
IGFBP-1. Exposure to IGF-I stimulated transglutamina-
tion of IGFBP-1 in vitro. An IGFBP-1 mutant in which
Gln66-Gln67 had been altered to Ala66-Ala67 (Q66A/Q67A)
was relatively resistant to polymerization by Tg com-
pared with native IGFBP-1. Tg localized in fibroblast
membranes was also shown to catalyze the formation of
native IGFBP-1 multimers, however, Q66A/Q67A IG-
FBP-1 failed to polymerize. Although the mutant IG-
FBP-1 potently inhibited IGF-I stimulated protein syn-
thesis in pSMC cultures, the same concentration of
native IGFBP-1 had no inhibitory effect. The addition of
higher concentrations of native IGFBP-1 did inhibit the
protein synthesis response, and this degree of inhibition
correlated with the amount of monomeric IGFBP-1 that
was present. In conclusion, IGFBP-1 is a substrate for
tissue transglutaminase and Tg leads to the formation of
high molecular weight covalently linked multimers. Po-
lymerization is an important post-translational modifi-
cation of IGFBP-1 that regulates cellular responses to
IGF-I.
Insulin-like growth factors (IGF-I and IGF-II)1 are associ-
ated with their specific binding proteins (IGFBPs) in extracel-
lular fluids, and these binding proteins regulate IGF actions (1,
2). The mechanisms responsible for IGFBP-induced changes
are not well defined. Several post-translational modifications
have been shown to alter the affinity of IGFBPs for IGFs,
including phosphorylation (3, 4), proteolysis (5, 6), and polym-
erization (7, 8). Dephosphorylation of human IGFBP-1 lowers
its affinity for IGF-I by 6-fold (9), and the addition of dephos-
phorylated IGFBP-1 to cells in culture has been shown to
enhance the capacity of IGF-I to stimulate DNA synthesis (1,
10). In contrast, phosphorylated IGFBP-1 inhibits IGF-I ac-
tions (2, 10). Our laboratory has previously demonstrated that
polymerized forms of IGFBP-1 were present in human amniotic
fluid and were abundant in the chromatographic fractions of
IGFBP-1 purified from amniotic fluid that had the capacity to
potentiate IGF-I-stimulated thymidine incorporation into por-
cine smooth muscle cells (pSMC) (1, 7, 10). In contrast, chro-
matographic fractions of purified IGFBP-1 that inhibited IGF-I
actions had no detectable multimers (10). The mechanism(s)
accounting for the appearance of these multimers have not
been determined.
Tissue transglutaminase (transglutaminase type II) is a cal-
cium-dependent enzyme that catalyzes the formation of isopep-
tide cross-links between glutamine and lysine residues and
also can attach primary amines to peptide-bonded glutamines.
The isopeptide cross-links are stable and resistant to proteol-
ysis, thereby increasing resistance to chemical, enzymatic, or
mechanical disruption. Tissue transglutaminase (Tg) activity
is widely distributed in many tissues and organs, and it has
been localized to the cytoplasm (11), cell surface (12), and
extracellular matrix (13). The ability of some proteins to poly-
merize and form covalently linked multimers is dependent
upon this activity (14, 15). Therefore, we speculated that IG-
FBP-1 might be a substrate for tissue transglutaminase and
that polymerization of IGFBP-1 might change its ability to
modulate IGF-I actions in vitro. The current studies were un-
dertaken to determine whether tissue transglutaminase could
catalyze the polymerization of IGFBP-1, to identify the factors
that enhanced or inhibited polymerization, and to analyze the
effect of polymerization upon IGF-I actions.
EXPERIMENTAL PROCEDURES
Materials—pSMC were obtained from aortic explants and main-
tained in our laboratory as previously described (16). Human fetal
fibroblasts (GM 10) were purchased from the Human Mutant Genetic
Cell Repository (Camden, NJ). Calf serum was purchased from Colo-
rado Laboratories Inc. (Logan, UT). [35S]Methionine was from ICN
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Biomedical Inc. (Costa Mesa, CA). Tissue culture media, fetal calf
serum, penicillin, streptomycin, and Geneticin (G418) were from Life
Technologies, Inc. IGF-I was a gift from Genentech (South San Fran-
cisco, CA). Tissue transglutaminase and cystamine were purchased
from Sigma. Native IGFBP-1 was obtained from media conditioned by
CHO cells that had been transfected with an expression plasmid that
contained the human IGFBP-1 cDNA (CHOBP1-D6) as previously de-
scribed (3). Polyclonal rabbit antiserum for human IGFBP-1 was pre-
pared as previously described (17). A monoclonal antibody to tissue
transglutaminase was purchased from NeoMarker (Fremont, CA). Poly-
vinylidene difluoride transfer membranes were obtained from Millipore
Corp. (Bedford, MA).
Tissue Culture—Human fetal fibroblast (GM 10) cells were main-
tained in Eagle’s minimum essential medium (EMEM) (Life Technolo-
gies, Inc., Gaithersburg, MD) supplemented with 10% (v/v) calf serum,
penicillin (100 units/ml), and streptomycin (100 mg/ml). pSMC were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Life Tech-
nologies) supplemented with 10% fetal calf serum and antibiotics (100
units/ml penicillin and 100 mg/ml streptomycin). The medium was
changed on the third day after plating, and the cultures reached 80%
confluency in another 3 days, at which time they were used for exper-
iments. GM-10 cells were used between passages 8 and 16, and pSMC
were used between passages 4 and 8.
Polymerization of IGFBP-1 with Tissue Transglutaminase—IG-
FBP-1 (50 ng) was incubated with 0.5 microunits of pure tissue trans-
glutaminase (purified from guinea pig liver) in reaction buffer contain-
ing 100 mM Tris-HCl, 20 mM dithiothreitol, 2.5 mM CaCl2, 10% (v/v)
glycerol, pH 8.5, for the indicated times at 37 °C (final assay volume 30
ml). The reactions were terminated by the addition of 43 Laemmli
buffer containing 400 mM dithiothreitol and boiling for 10 min. The
proteins were analyzed by 10% SDS-PAGE with immunoblotting for
IGFBP-1 (7–9). The immune complexes were visualized using an alka-
line phosphatase-conjugated anti-rabbit IgG and a phosphatase-de-
pendent color development system as previously described (18). For
Western ligand blotting, the proteins were transferred to polyvinyli-
dene difluoride membranes; probed in 4.0 ml of 10 mM Tris-HCl, 150 mM
NaCl, 0.05% sodium azide, 1% bovine serum albumin (pH 7.4) contain-
ing 125I-IGF-I (100,000 cpm/ml), specific activity 125 mCi/mg; and then
washed and visualized by autoradiography as described previously (19).
Densitometric quantification of the bands was performed by scanning
the film and analyzing the band intensities using NIH Image.
Polymerization of IGFBP-1 in Human Fetal Fibroblast in Cul-
tures—GM 10 cells were grown to 80% confluency on 24-well culture
plates (Falcon Labware, division of Becton Dickinson, Franklin, NJ;
catalog no. 3047). The cultures were rinsed once with serum-free
EMEM and incubated for 5 h in 250 ml of same medium. After the
incubation, medium was replaced with serum-free EMEM containing 1
mg/ml of either native or dephosphorylated IGFBP-1 and incubated for
20–40 min at 37 °C, and then 30 ml of each sample was collected. The
reactions were terminated by the addition of 43 Laemmli buffer con-
taining 400 mM dithiothreitol. The reaction products were analyzed by
SDS-PAGE with Western immunoblotting for IGFBP-1.
Preparation of Membrane Extract from Human Fibroblasts—GM 10
cells were grown to confluency on 10-cm tissue culture dishes (Falcon;
catalog no. 3003). The cultures were rinsed with serum-free EMEM and
incubated overnight in the same medium in the presence or absence of
IGF-I (30 ng/ml). The cells were scraped from the dishes with a cell
scraper and washed three times with ice-cold Ca21- and Mg21-free
phosphate-buffered saline. The washed cells were sonicated in sonica-
tion buffer (20 mM Hepes, pH 7.4, 100 mM NaCl, 5 mM KCl, 0.3 mM
Na2HPO4, 1 mM NaHCO3, 250 mM sucrose, 1 mM phenylmethanesul-
fonyl fluoride, 1 mg/ml pepstatin, 1 mg/ml leupeptin). The cell lysate was
centrifuged at 16,000 3 g for 15 min, and the pellet was washed with
the sonication buffer twice, solubilized in the same buffer containing 10
mM CHAPS, and centrifuged at 16,000 3 g for 15 min. The transglu-
taminase activity in the detergent-soluble membrane extracts was de-
termined by adding 10.5 mg of membrane protein to 30 ml of the assay
buffer described previously except that the tubes also contained 25 ng of
IGFBP-1. To determine whether polymerization was being catalyzed by
Tg, some tubes contained cystamine (20 mM), a specific inhibitor of Tg
activity (20).
Plasmid Construction for Expression of the IGFBP-1 Mutant—A full-
length human IGFBP-1 cDNA was cloned into the HindIII and XbaI
sites of a mammalian expression vector pRcRSV (pRcRSV-hBP-1) that
was prepared from the plasmid pRcCMV (Invitrogen, La Jolla, CA). The
pRcRSV-hBP-1 contains a bacteriophage origin of replication that al-
lows production of plasmid DNA in a single-stranded form suitable for
site-directed mutagenesis. The mutant IGFBP-1 cDNA was generated
using site-directed mutagenesis (21). Single-stranded phagemid DNA
was generated from pRcRSV-hBP-1, and the substitutions were intro-
duced using synthetic oligonucleotide as a substrate for antisense DNA
synthesis. The sequence of complementary oligonucleotide was 39-CGT-
GCAGAGGTGCCGCCTCCCCCGGCA-59. This encoded conversions of
Gln66 to Ala and Gln67 to Ala (designated pRcRSV-hBP-1Q66A/Q67A).
The cDNA was sequenced, and the clones containing correct sequence
were amplified. The plasmid DNA was purified using silica gel anion
exchange resin chromatography (Qiagen, Chatsworth, MA).
Transfection of Chinese Hamster Ovary Cells—CHO-K1 cells were
obtained from Lineberger Comprehensive Center Tissue Culture Facil-
ity (University of North Carolina). Cells were maintained in a-modified
Eagle’s minimum essential medium containing 10% fetal calf serum,
penicillin, and streptomycin. CHO cells were transfected with the
pRcRSV-hBP-1Q66A/Q67A using a standard calcium phosphate precip-
itation procedure (22). The positive clones were selected with 800 mg/ml
of G418 and maintained in a long term culture in 400 mg/ml G418.
Protein Purification—The Q66A/Q67A mutant IGFBP-1 was purified
from conditioned medium of the pRcRSVhBP-1Q66A/Q67A-transfected
CHO cells using procedures identical to those used to purify native
IGFBP-1 as described previously (3). Twenty micrograms of native
IGFBP-1 was dephosphorylated by incubating it with 50 units of calf
intestinal alkaline phosphatase at 37 °C in 50 mM Tris-HCl, 0.1 mM
EDTA (pH 8.5) for 16 h and repurified by reverse phase high pressure
liquid chromatography. The purity of each form of IGFBP-1 was deter-
mined by SDS-PAGE with silver staining. Analysis of each form re-
vealed a single monomeric band.
[35S]Methionine Incorporation into pSMC—pSMC were grown to
80% confluency on 24-well culture plates. The cultures were rinsed once
with serum-free DMEM and incubated overnight in the same media.
After the incubation, media were replaced with 0.25 ml of methionine-
free DMEM supplemented with 2 mM CaCl2 for 4 h in the presence of
0.05 mCi/well [35S]methionine (specific activity, 1, 206 Ci/mmol), IGF-I
(0 or 50 ng/ml), and various concentrations of either native or mutant
IGFBP-1 (0–2,500 ng/ml). The plates were placed on ice, washed with
ice-cold phosphate-buffered saline twice, and incubated with 10% tri-
chloroacetic acid for 10 min. The trichloroacetic acid-precipitable radio-
activity was solubilized in 1% SDS, 0.1 N NaOH and scintillation mix-
ture (ScintiSafeTM Econo2; Fischer, Fair Lawn, NJ) and counted in a
liquid scintillation counter (Beckman Instruments). Statistical compar-
isons were performed using a paired Student’s t test.
RESULTS
IGFBP-1 Is a Substrate for Tissue Transglutaminase—Fol-
lowing exposure to pure tissue Tg, IGFBP-1 formed covalent
multimers that were stable during SDS-PAGE and were not
altered with reducing agents (Fig. 1A). Incubation with tissue
transglutaminase was associated with a time-dependent in-
crease in dimer and multimer formation (Fig. 1A). Scanning
densitometry showed that 57% of the total IGFBP-1 was pres-
ent as polymerized forms after 5 h of incubation. When increas-
ing concentrations of Tg were added, there was a progressive
increase in dimer formation (Fig. 1B).
Dephosphorylated IGFBP-1 Polymerizes More Readily Com-
pared with Native IGFBP-1—To determine whether the phos-
phorylation status of IGFBP-1 affects its ability to polymerize,
dephosphorylated IGFBP-1 (50 ng) was incubated with increas-
ing concentrations of tissue Tg (0–1.0 microunits/tube) for 30
min at 37 °C, and the products of the reaction were analyzed by
SDS-PAGE using reduced conditions (Fig. 2). Dephosphoryl-
ated IGFBP-1 polymerized after exposure to 0.1 microunits of
tissue Tg, whereas native IGFBP-1 required 0.4 microunits
(Fig. 1B) or 0.5 microunits (Fig. 2) of Tg to detect polymeriza-
tion. Dephosphorylated IGFBP-1 polymerized to a greater ex-
tent with each concentration of tissue Tg that was used. There-
fore, dephosphorylation of IGFBP-1 enhances its susceptibility
to Tg-catalyzed polymerization in vitro.
Alteration of Residues Gln66 and Gln67 in IGFBP-1 Inhibits
Its Polymerization by Tissue Transglutaminase—To determine
whether the adjacent glutamine residues, Gln66 and Gln67,
were involved in the formation of Tg catalyzed polymerization,
the Q66A/Q67A IGFBP-1 mutant was incubated with various
concentrations of tissue Tg for 30 min at 37 °C, and the prod-
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ucts of the reaction were analyzed by SDS-PAGE using reduc-
ing conditions. The Q66A/Q67A mutant IGFBP-1 required 1.0
microunit of Tg to polymerize (Fig. 3), and only minimal
amounts of dimer were detected. In contrast, the same concen-
tration of native IGFBP-1 was polymerized to a much greater
extent by 0.5 microunits of Tg. This reveals that substitution
for Gln66-Gln67 in IGFBP-1 inhibits transglutamination and
that Gln66-Gln67 is probably one of the cross-linking sites in
IGFBP-1.
Enhancement of Polymerization of IGFBP-1 by IGF-I—Na-
tive IGFBP-1 was incubated with IGF-I at room temperature
for 30 min. The IGF-IzIGFBP-1 complex was then incubated
with 0.3 microunits of tissue Tg for 1 h at 37 °C, and the
reaction products were analyzed by SDS-PAGE using reducing
conditions (Fig. 4). The complexes containing IGF-I showed
enhanced polymerization of IGFBP-1 by Tg compared with
IGFBP-1 that was not exposed to IGF-I. Incubation with IGF-I
and no Tg had no effect.
Polymerization of IGFBP-1 by Exposure to Fetal Fibroblast
Cultures—Polymerization of IGFBP-1 had been observed pre-
viously in cell culture supernatants (7). Since tissue Tg is
widely distributed in many tissues and organs, we determined
if exposure of IGFBP-1 to fibroblast cultures would allow po-
lymerization. Native and dephosphorylated IGFBP-1 were po-
lymerized within 20 min, when IGFBP-1 (1 mg/ml) was added
to GM 10 fetal fibroblast cultures (Fig. 5). Dephosphorylated
IGFBP-1 was more readily polymerized compared with native
IGFBP-1 by cell-associated Tg.
Polymerization of IGFBP-1 Incubated with Fetal Fibroblast
Membrane Extract—Since tissue Tg is not secreted into the cell
culture medium, we hypothesized that the polymerization of
IGFBP-1 might be occurring on cell surfaces. To determine
FIG. 4. Enhancement of polymerization of IGFBP-1 by IGF-I.
Native IGFBP-1 (50 ng) was incubated with 1 ng of IGF-I for 1 h at room
temperature followed by the addition of 0.3 microunits/tube of tissue
transglutaminase, and the incubation was continued for 1 h at 37 °C.
The reaction products were analyzed by 10% SDS-PAGE with Western
immunoblotting using human IGFBP-1 antiserum. The bottom arrow
denotes the monomeric form, and the top arrow denotes the dimeric
form of IGFBP-1.
FIG. 1. Polymerization of IGFBP-1 with tissue transglutami-
nase. Native IGFBP-1 (50 ng) was incubated with 0.5 microunits (mU)/
tube of tissue transglutaminase for the indicated time periods (A) or
with increasing concentrations (0–0.5 microunits/tube) of tissue trans-
glutaminase for 30 min (B) at 37 °C. The reaction products were ana-
lyzed by 10% SDS-PAGE followed by immunoblotting using human
IGFBP-1 antiserum. The arrows denote monomer, dimer, and multimer
forms of IGFBP-1. For A, the intensities of all of the bands were
determined by scanning densitometry. The values shown represent the
percentage of total scanning units that was detected as the IGFBP-1
monomer.
FIG. 2. Polymerization of dephosphorylated IGFBP-1 with in-
creasing concentrations of tissue transglutaminase. Dephospho-
rylated IGFBP-1 was prepared as described under “Experimental Pro-
cedures.” To determine whether its phosphorylation state would affect
its polymerization, native IGFBP-1 (N) or dephosphorylated IGFBP-1
(D) (50 ng) was incubated with increasing concentrations (0.1–1.0 mi-
crounits (mU)/tube) of tissue transglutaminase for 30 min at 37 °C. The
reaction products were analyzed by 10% SDS-PAGE with Western
immunoblotting using human IGFBP-1 antiserum. The bottom arrow
denotes the monomeric form, and the top arrow denotes the dimeric
form of IGFBP-1.
FIG. 3. Polymerization of Q66A/Q67A mutant IGFBP-1 with
increasing concentrations of tissue transglutaminase. Native IG-
FBP-1 (N) or Q66A/Q67A mutant IGFBP-1 (Q) (50 ng) was incubated
with increasing concentrations (0.1–1.0 microunits (mU)/tube) of tissue
transglutaminase for 30 min at 37 °C. The reaction products were
analyzed by 10% SDS-PAGE with Western immunoblotting using hu-
man IGFBP-1 antiserum. The bottom arrow denotes the monomeric
form, and the top arrow denotes the dimeric form of IGFBP-1.
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whether cellular membrane extracts could facilitate polymeri-
zation of IGFBP-1 and whether IGF-I altered the extent of
polymerization, IGFBP-1 was incubated with fibroblast mem-
brane extracts. Cell membrane extracts were prepared from
cells that had been incubated for 14 h, and the samples were
analyzed by SDS-PAGE under the reducing conditions (Fig.
6A). Exposure of the cultures to IGF-I enhanced polymerization
of both phosphorylated and dephosphorylated IGFBP-1 com-
pared with membrane extracts from control cultures exposed
only to serum-free medium. However, if IGF-I was added in
vitro directly to the membrane extract, the extent of polymer-
ization was much greater. When cystamine, a specific inhibitor
of Tg, was coincubated with IGFBP-1 and the membrane ex-
tracts, no polymerization was observed (Fig. 6B). Fig. 6C shows
that these cellular membrane extracts contained equivalent
concentrations of Tg.
Q66A/Q67A Mutant IGFBP-1 Inhibits IGF-I-stimulated
Protein Synthesis on pSMC in Culture—pSMC were grown to
80% confluency in 24-well culture plates and the ability of IGF
to stimulate [35S]methionine incorporation into protein was
determined. IGF-I stimulated the incorporation of [35S]methi-
onine into pSMC by 60% above the basal level. The addition of
native IGFBP-1 at concentrations as high as 1,000 ng/ml re-
duced this response by 20%, although the decrease was not
significant (p 5 NS). Native IGFBP-1 (2,500 ng/ml) was re-
quired to obtain complete inhibition. In contrast, the addition
of 1,000 ng/ml Q66A/Q67A mutant IGFBP-1 resulted in com-
plete inhibition of protein synthesis that had been stimulated
by IGF-I (p , 0.001) (Fig. 7). Analysis of the forms of IGFBP-1
that were present in the media at the end of the incubation
showed that the native IGFBP-1 polymerized, but the Q66A/
Q67A mutant IGFBP-1 was present only in the monomeric
form. The scanning densitometric values of 1,000 ng/ml of
mutant IGFBP-1 and 2500 ng/ml of native IGFBP-1 showed
that approximately the same amount of monomeric IGFBP-1
was present. When the polyvinylidene difluoride membrane
was probed with radiolabeled IGF-I, the intensity of the native
IGFBP-1 monomeric band was reduced compared with Q66A/
Q76A mutant IGFBP-1 monomer. More importantly, the native
IGFBP-1 polymeric form did not bind to radiolabeled IGF-I,
and no band could be detected.
DISCUSSION
The current studies demonstrate that IGFBP-1 is a substrate
for tissue Tg and that Gln66-Gln67 is a one of the amine accep-
tor sites in IGFBP-1. This polymerization-resistant mutant
FIG. 6. Polymerization of IGFBP-1 incubated with GM 10 fetal
fibroblast membrane extracts. GM 10 cells were grown to conflu-
ency on 10-cm tissue culture plates. In A, the cells were incubated with
serum-free EMEM in the absence (lanes a and b) or presence (lane c) of
IGF-I (30 ng/ml). After the incubation, the cellular membrane extracts
were prepared as described under “Experimental Procedures.” Each
membrane extract was incubated with either native (N) or dephospho-
rylated IGFBP-1 (D) (25 ng) in the absence (lanes a and c) or presence
(lane b) of IGF-I (1 ng/tube) for 14 h at 37 °C. The reactions were
analyzed by SDS-PAGE with immunoblotting for IGFBP-1 (A). The
bottom arrow denotes the monomeric form, and the top two arrows
denote the dimeric and trimeric forms of IGFBP-1, respectively. B, the
membrane extract was incubated with dephosphorylated IGFBP-1 (25
ng) in the presence and absence of cystamine (20 mM) for 6 h at 37 °C.
The reactions were analyzed by SDS-PAGE with immunoblotting for
IGFBP-1. C, the same membrane extracts were analyzed by SDS-PAGE
and immunoblotted with anti-tissue transglutaminase antibody.
FIG. 7. [35S]methionine incorporation into pSMC protein syn-
thesis was measured using [35S]methionine incorporation into
protein as described under “Experimental Procedures.” pSMC
were grown to 80% confluency on 24-well tissue culture plates. The
cultures were incubated with serum-free DMEM for overnight, and
then media were replaced with methionine-free DMEM containing 0 or
50 ng/ml of IGF-I, different concentrations of either native (l) or Q66A/
Q67A mutant IGFBP-1 (Œ), and [35S]methionine for 4 h. The amount of
[35S]methionine activity incorporated into cellular protein was meas-
ured. The results are expressed as a percentage of increase over control
cultures that were incubated with methionine-free DMEM without
IGF-I or IGFBP-1. Each value is mean 6 S.E. of triplicate determina-
tions. The inset shows a Western ligand blot and immunoblot of the
media samples obtained at the end of the incubation from the cultures
exposed to 20 ml of native or Q66A/Q67A IGFBP-1. The scanning units
that were detected in the monomeric band (lower arrow) are shown.
FIG. 5. Polymerization of IGFBP-1 incubated with GM 10 fetal
fibroblasts in culture. GM 10 cells were grown to 80% confluency on
24-well tissue culture plates. Cells were incubated with serum-free
EMEM containing either native (N) or dephosphorylated (D) IGFBP-1
(1 mg/ml) for the indicated times. Thirty microliters of each sample was
collected and analyzed by SDS-PAGE with immunoblotting. The bottom
arrow denotes the monomeric form, and the top arrow denotes the
dimeric form of IGFBP-1.
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form of IGFBP-1 potently inhibits IGF-I-stimulated protein
synthesis into pSMC. In contrast, when polymerizable native
IGFBP-1 was added, much higher concentrations were re-
quired to inhibit IGF-I action. The polymerization of IGFBP-1
by tissue Tg was also shown to be altered by the phosphoryla-
tion state of IGFBP-1 and by the presence of IGF-I in the
incubation buffer.
Numerous proteins have been demonstrated as substrates
for Tg; however, a general consensus recognition sequence for
transglutaminase has not been determined. Two directly adja-
cent glutamine residues have frequently been identified as
amine-accepting sites. The g-chain of fibrinogen (23) and fi-
bronectin (24), which contain adjacent glutaminase residues,
are substrates for factor XIIIa. Plasminogen activator inhibi-
tor-2 (25), b A3-crystallin (26), and BM-40 (osteonectin) (27) are
substrates for tissue Tg, and they have two directly adjacent
glutamine residues that have been identified as amine acceptor
sites. In addition, positively or negatively charged amino acid
residues are often found near amine acceptor sites in the se-
quence of these proteins. Analysis of the sequences following
Gln66-Gln67 in IGFBP-1 showed that both positively (Glu65)
and negatively (His70) charged residues are present (Fig. 8).
The positions of charged residues in several other substrates
for tissue Tg are shown for comparison. Because of these sim-
ilarities, we speculated that the adjacent glutamine residues in
IGFBP-1 (Gln66-Gln67) could be amine acceptor sites. The
Q66A/Q67A mutant form of IGFBP-1 that was generated was
resistant to polymerization by pure tissue Tg and following
exposure to cell cultures that contained tissue Tg in their
membrane extracts. These findings strongly support the con-
clusion that tissue Tg is using these residues as amine acceptor
sites for cross-linking in IGFBP-1.
IGFBP-1, -2, -3, and -5 have been shown to stimulate or
inhibit IGF-I actions in vitro (28). Most studies have shown
that excess concentrations of IGFBP-1 inhibit the IGF-I actions
in vitro, particularly if high concentrations of IGFBP-1 are
added using serum-free conditions (2, 10, 29–31). When plate-
let-poor plasma is added with IGF-I and dephosphorylated
IGFBP-1, IGFBP-1 has been shown to potentiate the IGF-I-
stimulated DNA synthesis in cultured fibroblasts and pSMC
(1). The phosphorylation state of IGFBP-1 was also shown to be
an important determinant of this response, and dephosphoryl-
ated IGFBP-1 was much more effective than phosphorylated
IGFBP-1 (1, 9, 32). Analysis of the cell culture supernatants at
the end of these incubations showed that the added IGFBP-1
had polymerized. Therefore, the current studies were under-
taken to determine whether IGFBP-1 polymerized as a result
of exposure to transglutaminase, if its phosphorylation status
of IGF-I affected its capacity to polymerize, and if polymeriza-
tion would be associated with a decrease in the ability to inhibit
IGF-I-stimulated protein synthesis.
IGFBP-1 is a phosphoprotein that undergoes serine phospho-
rylation (9). Several phosphoisoforms of IGFBP-1 have been
detected in serum, and the presence of highly phosphorylated
forms of IGFBP-1 in physiologic fluids has been associated with
conditions in which the target tissue actions of IGF-I are being
inhibited (32, 33). Separation of phosphoisoforms of IGFBP-1
by anion exchange chromatography has shown that chromato-
graphic fractions that contain phosphorylated forms inhibit
IGF-I actions, whereas those that are enriched in nonphospho-
rylated forms did not inhibit IGF-I actions (9, 10, 28). In this
study, dephosphorylated IGFBP-1 polymerized to a much
greater extent compared with phosphorylated IGFBP-1. Since
the ability of IGFBP-1 to polymerize has also been shown to be
related to the loss of its capacity to inhibit IGF-I actions, these
results suggest that this may be one mechanism by which
phosphorylation of IGFBP-1 may enhance its capacity to in-
hibit IGF-I actions.
The results of several studies have shown that the loss of the
ability of IGFBP-1, IGFBP-3, and IGFBP-5 to inhibit IGF-I
actions is associated with a reduction in their affinities for
IGF-I (9, 34–38). IGFBPs have high affinity for IGF-I, and
their affinities are greater than that of the type-I IGF receptor.
Therefore, factors such as dephosphorylation (3) or adherence
to cell surfaces (18), which lower their affinity for IGF-I, will
reduce their capacity to inhibit IGF-I actions, and in some cases
this has been associated with stimulation of IGF-I actions (1).
Our results showed that the multimeric form of IGFBP-1 (Fig.
7) that occurred following transglutamination had very low
binding capacity for IGF-I and that polymerization was asso-
ciated with a loss of IGFBP-1’s inhibitory effect. Immunoblot-
ting analysis at the end of incubation revealed that the concen-
tration of monomeric IGFBP-1 correlated with the extent of
inhibition of IGF-I action. This result suggests that polymeri-
zation is also an important mechanism by which the inhibitory
effect of IGFBP-1 is attenuated.
The N-terminal domain of IGFBP-3 and -5 contain a binding
site for IGF-I (39). In IGFBP-5, the IGF-I binding site is con-
tained within amino acids 49–74, and in IGFBP-3 it is between
residues 50 and 75. For IGFBP-5, the charged residue Lys68
and the hydrophobic residues Pro69, Leu70, Leu73, and Leu74
are required for binding. In the IGFBP-1, residues Pro68, Leu69,
and Leu70 are homologous, suggesting that this is also an
important site in IGFBP-1 for IGF-I binding. Our results dem-
onstrate that following transglutamination, which occurs
through Gln66-Gln67, the affinity of IGFBP-1 is markedly re-
duced. This suggests that cross-linking through these sites
alters the conformation of the adjacent IGF-I binding site such
that IGF-I has reduced access.
Our results also show that IGF-I stimulates the polymeriza-
tion of IGFBP-1 by pure tissue Tg and by the Tg that was
contained in fibroblast membrane extracts. The effect is direct
and does not require the presence of some other component.
Since IGF-I is probably binding to the region of IGFBP-1 that
contains the amine acceptor sites, its presence may induce a
conformational change in IGFBP-1 that stabilizes the confor-
mation of the multimeric forms and facilitates cross-linking by
tissue Tg.
Recently, tissue Tg has been shown to associate with b1 and
b3 integrins, and it has been estimated that 5–40% of b1
integrins on the cell surface are complexed with tissue trans-
glutaminase. Tissue Tg on the cell surface has been shown to
FIG. 8. Comparison of amino acid sequences flanking the two adjacent glutamine residues that have been identified as amine
acceptor sites. Two adjacent glutamine residues (amine acceptor site) are underlined, and charged residues are in boldface type for IGFBP-1 and
other proteins that have been noted to undergo transglutamination.
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increase cell adhesion and spreading on fibronectin (40). IG-
FBP-1 has been shown to bind to the a5b1 integrin and stimu-
late cell migration independently of IGF-I (41). Ligand occu-
pancy of a5b1 by IGFBP-1 has been shown to induce focal
adhesion kinase and PI 3-kinase. Therefore, IGFBP-1 could
form an IGFBP-1-tissue Tg complex with the b1 integrin, and
transglutamination of IGFBP-1 could potentially modulate the
a5b1 integrin-linked signaling. Elucidation of the interaction
between IGFBP-1 and tissue Tg will be a great help in further
analysis of the biological significance of multiple IGFBP-1/
IGF-I interactions that occur in vivo.
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